Company Statement: GSK announces expiration of HSR for Human Genome bid
MLex Summary: The initial Hart-Scott-Rodino Act waiting period for GlaxoSmithKline's tender offer for all outstanding shares of Human Genome Sciences has expired without incident. The full statement follows:...To view the full article, register now.
Already a subscriber? Click here to view full article